Oestrogen treatment of adolescent tall girls; short term side effects.
In 1980-1985 680 preadolescent tall girls were treated with pharmacological doses of oestrogen to reduce final height. Indications for the therapy were predicted final height greater than +2.5 SD (180.75 cm), idiopathic scoliosis, and psychosocial problems. Until 1976 141 girls were given diethyl stilboestrol 5 mg daily. By advice of Prader this was then replaced by ethinyl oestradiol and a progestin was given on days 5-10 each month. The mean duration of therapy was close to 2 years. The observed short-term unwanted effects were due to the pharmacological actions of the drugs, (11 girls had galactorrhoea at the end of therapy; no pituitary prolactinoma was observed) or events happening by chance.
Trygstad
O
O
D000236:Adenoma / Q000139:chemically induced; D000293:Adolescent; D001971:Bromocriptine / Q000627:therapeutic use; D002648:Child; D004054:Diethylstilbestrol / Q000009:adverse effects / Q000627:therapeutic use; D004967:Estrogens / Q000009:adverse effects* / Q000627:therapeutic use; D004997:Ethinyl Estradiol / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D005687:Galactorrhea / Q000139:chemically induced; D006130:Growth Disorders / Q000188:drug therapy*; D006801:Humans; D010911:Pituitary Neoplasms / Q000139:chemically induced
D004967:Estrogens; D001971:Bromocriptine; D004997:Ethinyl Estradiol; D004054:Diethylstilbestrol